|
|
|
10.08.26 - 17:18
|
RocketLab Rises on Space Interest; Moderna Moves on Flu Shot | Stock Movers (Bloomberg)
|
|
|
On this episode of Stock Movers:
- RocketLab (RKLB) shares are higher this morning after rising Friday, following earnings from SpaceX last week.
- Moderna (MRNA) shares are moving after last week's news that its mRNA flu shot won US approval in an FDA turnaround.
- Intel (INTC) shares are moving after the company said it will be offering $15 billion in common stock, taking advantage of renewed interest in its business prospects during the artificial intelligence data center boom. (Source: Bloomberg)...
|
|
|
10.08.26 - 13:45
|
Moderna-Aktie: Plötzlich deutlich besser als BioNTech (Sharedeals)
|
|
|
Die Moderna-Aktie überrascht die Börse rund um das Wochenende mit einem neuen Höhenflug. Nachdem der Kurs des Biotech-Konzerns bereits am Freitag um +10% in die Höhe geschossen ist, setzt sich die gute Performance auch am Montagvormittag im europäischen Handel mit einem Kursplus von über +3% fort. Was steckt hinter dem Kurssprung von Moderna und ist […]
The post Moderna-Aktie: Plötzlich deutlich besser als BioNTech first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.08.26 - 18:24
|
Moderna′s mRNA Flu Vaccine Approved By FDA (ZeroHedge)
|
|
|
Moderna's mRNA Flu Vaccine Approved By FDA
Authored by Rachel Roberts via The Epoch Times,
The U.S. Food and Drug Administration has approved Moderna's flu shot for over-50s, marking the first time the agency has licensed a messenger ribonucleic acid (mRNA) vaccine for seasonal influenza.
Moderna bivalent COVID-19 vaccine at a clinic, in Richmond, Va., on November 17, 2022. AP Photo/Steve Helber, File
The shot, known as mFlusiva, was given a traditional approval for adults aged 50 to 64, and an accelerated approval for the over-65s, the pharmaceutical giant said on Wednesday.
Moderna has agreed to run an additional study and submit further data on the over-65s in a bid to demonstrate the vaccine's benefit for that age group.
The approval was based on data from a late-stage trial involving more than 40,000 adults aged 50 and older, which found the shot was 26.5 percent more effective than a licensed standard-dose flu vaccine.
Moderna had to submit separate late-stage data showing the shot ge...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
